Anti-Granulocyte–Macrophage Colony–Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial

RATIONALE: GM-CSF (granulocyte–macrophage colony–stimulating factor) has emerged as a promising target against the hyperactive host immune response associated with coronavirus disease (COVID-19). OBJECTIVES: We sought to investigate the efficacy and safety of gimsilumab, an anti–GM-CSF monoclonal an...

Descripción completa

Detalles Bibliográficos
Autores principales: Criner, Gerard J., Lang, Frederick M., Gottlieb, Robert L., Mathews, Kusum S., Wang, Tisha S., Rice, Todd W., Madduri, Deepu, Bellam, Shashi, Jeanfreau, Robert, Case, Amy H., Glassberg, Marilyn K., Lyon, George Marshall, Ahmad, Kareem, Mendelson, Robert, DiMaio, J. Michael, Tran, MaryAnn P., Spak, Cedric W., Abbasi, Jamil A., Davis, Steven G., Ghamande, Shekhar, Shen, Steven, Sherman, Lisa, Lowry, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873114/
https://www.ncbi.nlm.nih.gov/pubmed/35290169
http://dx.doi.org/10.1164/rccm.202108-1859OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873114/
https://www.ncbi.nlm.nih.gov/pubmed/35290169
http://dx.doi.org/10.1164/rccm.202108-1859OC

Ejemplares similares